GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
What is PD1 and PDL1 in Kidney Cancer?
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and ...
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.
-
HD
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
The doctors discuss the new FDA-approved drug for ALK positive ...
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
-
HD
No Clear Answer for Non-Clear Cell Kidney Cancer
Drugs in early stage clinical trials seem to show benefit ...
Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.
-
HD
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
"Dead negative," is how Dr. Nasser Hanna describes results of ...
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
-
HD
Treating Newly Diagnosed Kidney Cancer
Dr. Guru Sonpavde discusses what he does when he first ...
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.
-
HD
MET-Amplified Lung Cancer: A New Target for XALKORI?
Lung cancer patients with high MET amplification appear to do ...
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
-
HD
The Hottest Thing in Late Stage Kidney Cancer
Patients are responding very well to the next generation of ...
Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.
-
HD
CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer
Lung cancer patients with the EGFR mutation who had progressed ...
Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.
-
HD
The Promise of PD1 Inhibitors in Kidney Cancer
Results from recent clinical trials looking into PD1 inhibitors of ...
Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.
-
HD
FGFR and Its Role in Treating Squamous Cell Lung Cancer
Fibroblast growth factor receptor (FGFR) mutations may play a role ...
Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.
